Dynamic Fluctuation of Circulating Tumor Cells duringCancer Progression

Cancers

卷:6

Alexander V. Melerzanov¹  Dmitry A. Nedosekin²  Ekaterina I. Galanzha²  Mazen A. Juratli²  Vladimir P. Zharov²  Mustafa Sarimollaoglu² 

[1] Moscow Institute of Physics and Technology (MIPT), Moscow Region, 141700, Russia;

[2] Phillips Classic Laser and Nanomedicine Laboratories, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA;

关键词: circulating tumor cells (CTCs);    CTC dynamics;    quantitative heterogeneity;    in vivo flow cytometry;    photoacoustics;    personalized diagnosis and therapy;   

DOI  :  10.3390/cancers6010128

来源: DOAJ

【 摘 要 】

Circulating tumor cells (CTCs) are a promising diagnostic and prognostic biomarker for metastatic tumors. We demonstrate that CTCs’ diagnostic value might be increased through real-time monitoring of CTC dynamics. Using preclinical animal models of breast cancer and melanoma and in vivo flow cytometry with photoacoustic and fluorescence detection schematics, we show that CTC count does not always correlate with the primary tumor size. Individual analysis elucidated many cases where the highest level of CTCs was detected before the primary tumor starts progressing. This phenomenon could be attributed to aggressive tumors developing from cancer stem cells. Furthermore,real-time continuous monitoring of CTCs reveals that they occur at highly variable rates in a detection point over a period of time (e.g., a range of 0–54 CTCs per 5 min). These same fluctuations in CTC numbers were observed in vivo in epithelial and non-epithelial metastatic tumors, in different stages of tumor progression, and in different vessels. These temporal CTC fluctuations can explain false negative results of a one-time snapshot test in humans. Indeed, we observed wide variations in the number of CTCs in subsequent blood samples taken from the same metastatic melanoma patient, with some samples beingCTC-free. If these phenomena are confirmed in our ongoing in vivo clinical trials, this could support a personalized strategy of CTC monitoring for cancer patients.

【 授权许可】

Unknown